Abstract
Metformin is the first line drug for patients with type-2 diabetes. The impact of different treatment escalation strategies after metformin failure on glucose control and morbidity has however not been investigated in real life. DiaRegis is a multicenter registry in 3,810 patients with type-2
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
